Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. (NASDAQ: FBRX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead program, FB102. The company describes FB102 as a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, and its press releases focus on clinical progress, financial updates and capital-raising activities related to this program.
News about Forte Biosciences frequently covers clinical trial milestones for FB102, including a phase 2 trial in celiac disease and phase 1b trials in vitiligo and alopecia areata. The company has issued releases discussing positive phase 1b data in celiac disease, additional data presentations at scientific meetings, and expectations for future clinical readouts. These updates provide insight into how Forte interprets emerging data for FB102 across multiple autoimmune indications.
Investors following FBRX can also see quarterly financial results reported via press releases that summarize research and development spending, general and administrative expenses and net loss, along with references to the company’s Form 10-Q filings. Other regular news items include public offering announcements, such as the pricing of common stock and pre-funded warrant offerings, and equity inducement grants made under Forte’s inducement equity incentive plan for new employees, as required by Nasdaq listing rules.
In addition, Forte issues notices about conference presentations at healthcare and investor events where management discusses FB102 and the company’s clinical strategy. Together, these news items offer a view into Forte’s clinical development timeline, financing approach and corporate activities for those researching Forte Biosciences and its FBRX stock.
Forte Biosciences has appointed Dr.
Forte Biosciences, Inc. (NASDAQ: FBRX) reported significant progress with its lead program, FB-102, which is projected to enter clinical trials in late 2023 or early 2024. The company ended Q3 2022 with approximately $44 million in cash. Appointing Dr. Scott Brun to the board strengthens its leadership, as he brings extensive pharmaceutical experience. Q3 operating expenses decreased to $3.4 million from $7.7 million year-over-year, primarily due to the winding down of the FB-401 program. However, net losses were reported at $3.4 million, compared to $7.8 million in Q3 2021.
Camac Partners, LLC, a major shareholder of Forte Biosciences, Inc. (FBRX), has expressed serious concerns regarding the company's management and board decisions. They noted that Forte's shares have plummeted approximately 95% since its IPO, trading at a 40% discount to its cash reserves of $45 million. The board's recent dilutive capital raise is viewed by Camac as self-serving and lacking justification. Camac urges the board to reconsider its capital allocation strategy and return funds to shareholders, threatening potential legal action if governance issues continue.
Forte Biosciences (NASDAQ: FBRX) reported its second quarter 2022 results, ending with $38.5 million in cash. The company is advancing its pipeline for autoimmune diseases, targeting markets exceeding $6 billion. Notable appointments include Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board. Research and development costs decreased due to the winding down of the FB-401 program. Despite a net loss of $3.0 million for the quarter, Forte aims to launch its lead molecule, FB-102, in late 2023 or early 2024.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced the appointment of Dr. Hubert Chen as Chief Scientific Officer and President. Dr. Chen brings extensive experience in drug development, previously serving as Chief Medical Officer at Metacrine and Chief Scientific and Medical Officer at Pfenex. His leadership is expected to strengthen Forte's focus on autoimmune diseases, particularly with their lead product FB-102. CEO Paul Wagner expressed confidence in Dr. Chen's expertise during this pivotal time for the company.
Forte Biosciences, Inc. (NASDAQ: FBRX) has announced an equity inducement award of 250,000 shares of common stock to Dr. Hubert Chen, who has joined as Chief Scientific Officer and President. This award, part of the company's 2020 Inducement Equity Incentive Plan, vests over four years, with 25% vesting after one year. Forte is focused on developing treatments for autoimmune diseases, with its lead product, FB-102, being proprietary. The company cautions that forward-looking statements are subject to risks that may affect actual results.
Forte Biosciences (NASDAQ: FBRX) recently announced its first quarter 2022 results, ending with approximately $40 million in cash. The company is shifting focus to develop FB-102, a novel treatment for autoimmune diseases, with potential market value exceeding $6 billion. The company appointed Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to its Board of Directors, enhancing leadership experience. Research and development expenses have decreased significantly, with a net loss of $2.57 million for the quarter, an improvement from $4.80 million year-over-year.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that the topline data from its Phase 2 clinical trial of FB-401 for atopic dermatitis did not achieve statistical significance for the primary endpoint, EASI-50. While positive trends were noted in secondary endpoints, such as EASI-90, achieving success rates of 27.6% versus 20.5% in the control arm, the trial's primary endpoint showed 58% success compared to 60% in the placebo group. Following this setback, the company will not advance FB-401 and will update investors on future plans in the coming months. As of June 30, 2021, cash reserves were $50.8 million.
Forte Biosciences, Inc. (NASDAQ: FBRX) is set to announce topline data from its Phase 2 trial of FB-401 for treating atopic dermatitis on September 7, 2021. This follows the completion of a Phase 1/2a study showing promising safety and efficacy in pediatric and adult patients. The upcoming data release coincides with a conference call on the same day. Forte aims to meet the unmet need for effective therapies in pediatric atopic dermatitis, particularly after initiating a multi-center, placebo-controlled trial, which began in September 2020.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced an equity inducement award for purchasing 90,000 shares of common stock to a new non-executive employee. This grant, approved by the Compensation Committee, serves as a material inducement for employment and will vest over four years. The award aligns with the terms of Forte's 2021 Equity Incentive Plan. Forte is a clinical-stage biopharmaceutical company focused on developing FB-401 for treating inflammatory skin diseases, including pediatric atopic dermatitis, with ongoing clinical trials demonstrating safety and activity across various age groups.